“Olfactory intelligence vision to drive innovation in healthcare, home appliances, and the metaverse”
Seoul, South Korea – JENLiFE (CEO Jinwoo Oh), a functional biomaterials startup specializing in electronic nose technology, today announced its participation in CES 2026, to be held in Las Vegas from January 6 to 9, 2026. The company will also compete for the CES Innovation Awards, one of the industry’s most prestigious recognitions.
A New Frontier in Olfactory Intelligence
Held annually in January, CES is one of the world’s three largest IT exhibitions, organized by the Consumer Technology Association (CTA). With over 3,200 exhibitors, CES highlights transformative products and technologies, and its Innovation Awards program recognizes only about 10 percent of applicants, with less than 1 percent achieving the coveted Best Innovation Award.
Against this backdrop, JENLiFE will present its M13 bacteriophage–based electronic nose platform, offering a breakthrough in mimicking human olfactory receptors and opening new possibilities for healthcare, consumer products, and immersive digital experiences.
Core Technology: M13 Bacteriophage-Based Electronic Nose
Unlike conventional gas sensors with limited detection ranges, JENLiFE uses phage display technology to create peptide receptors on M13 bacteriophages. These bio-receptors mimic human olfactory sensors, enabling the detection and identification of odor molecules with high sensitivity and selectivity.
Key features include:
• Broad detection capacity: Capable of identifying 800+ odor molecules through bio-receptor libraries.
• High reproducibility: Identical bacteriophages can be replicated consistently, ensuring stable performance.
• Scalability: Multiple bacteriophages can be arranged on sensors for diverse applications.
Through this platform, JENLiFE envisions an “olfactory intelligence” ecosystem, where odor data can be analyzed and predicted for practical use across industries.
Applications Across Industries
- Healthcare: Non-invasive diagnosis through breath and body odor analysis, enabling early detection of diseases such as lung cancer, diabetes, and oral disorders.
• Home Appliances: Adaptive air purification systemsthat respond automatically to air quality.
• Food Safety: Sensors that monitor spoilage levels for safer distribution and consumption.
• Disaster Response: Robots capable of detecting survivors or hazardous chemical leaks.
• Metaverse & Entertainment: Scent integration for enhanced realism in immersive experiences.
The company is actively collaborating with partners in consumer electronics, food, and automotive sectors to bring its electronic nose technology to market.
CES 2026 as a Global Launchpad
At CES 2026, JENLiFE will conduct live demonstrations of its platform, directly showcasing real-world performance to industry experts, buyers, investors, and media.
“We will showcase how our M13 bacteriophage-based electronic nose platform works in practice,” said a JENLiFE spokesperson. “Through this, we aim to highlight its strengths and applications, while actively pursuing collaborations and investment opportunities.”
The spokesperson added:
“By leveraging insights and networks from CES 2026, we intend to establish a foothold in the U.S. and other global markets, forming partnerships with bio, electronics, and robotics companies and institutions.”
About JENLiFE
JENLiFE is a Korean startup specializing in functional biomaterials and next-generation electronic nose technology. Its proprietary M13 bacteriophage–based platform mimics human olfaction with high precision, delivering applications in healthcare, consumer electronics, robotics, and immersive digital environments. By combining biotechnology with data-driven analysis, JENLiFE aims to pioneer the field of olfactory intelligence and redefine global standards in smart sensing solutions.
Press Contact
Jinwoo Oh
CEO
JENLiFE
Email: info@jen-life.com